FreeTheAI

FDA Grants Priority Review for CorMedix sNDA Seeking REZZAYO Expansion

BullishMedium impact
CRMD$7.38 1.65%

The U.S. Food and Drug Administration accepted a supplemental New Drug Application seeking approval for REZZAYO (rezafungin for injection) to prevent invasive fungal diseases in adult stem cell transplant patients. Submitted by global development partner Mundipharma, the filing received Priority Review status with a target decision date set for the first quarter of 2027. Shares of CorMedix Inc. (NASDAQ:CRMD) dropped 2.68% to $7.26 following the announcement.

REZZAYO is currently approved to treat candidemia and invasive candidiasis in patients aged 12 and older who have limited treatment options. Expanding its use to prevention in adults undergoing allogeneic stem cell transplants addresses a high-risk population where invasive fungal infections carry significant mortality risks. The filing is supported by positive Phase III clinical trial results, and the drug maintains orphan exclusivity through 2035 alongside patent protection through 2038 in the United States.

Investors and healthcare providers will look toward the regulator's expected decision in early 2027. If granted approval for the preventive indication, CorMedix Therapeutics plans to launch commercial promotional activities during the second half of 2027.

Key points

  • The FDA accepted Mundipharma's supplemental application for REZZAYO with Priority Review and a Q1 2027 action date.
  • The application seeks approval for rezafungin to prevent invasive fungal disease in adults receiving stem cell transplants.
  • Approval efforts are backed by positive Phase III ReSPECT trial data comparing rezafungin to standard antimicrobial care.
  • CorMedix Inc. (NASDAQ:CRMD) aims to start commercial promotional efforts in the second half of 2027 if approved.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did the FDA decide regarding CorMedix's REZZAYO application?

The FDA accepted the supplemental New Drug Application for REZZAYO for filing with Priority Review, setting a target decision date in the first quarter of 2027.

What new indication is CorMedix seeking for REZZAYO?

CorMedix and partner Mundipharma are seeking approval for REZZAYO to prevent invasive fungal diseases in adult patients undergoing allogeneic stem cell transplants.

When could REZZAYO launch for fungal disease prevention if approved?

If the FDA grants approval, CorMedix targets starting promotional and commercial launch efforts in the second half of 2027.